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Edited by Peter BrzezinskiAbstract Calpastatin is the endogenous, speciﬁc protein inhibi-
tor of the calcium-dependent protease, calpain. Using an active
site knock-out m-calpain mutant we have studied the enzyme’s
calcium-dependent binding to calpastatin by surface plasmon res-
onance without the complication of proteolysis. Calpastatin was
capable of simultaneously binding four molecules of calpain. Its
four inhibitory domains (CAST1, 2, 3, and 4) were individually
expressed in Escherichia coli and the kinetics of their interaction
with calpain was separately compared. Their Kd values ranged
from picomolar to nanomolar in the order CAST1 > 4 > 3 > 2.
They have similar kon values but the koﬀ values ranged over three
orders of magnitude and can account for the diﬀerences in aﬃn-
ity.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Calpains are a family of cytosolic Ca2+-dependent cysteine
proteases that have been best characterized in animals, but
are also found in plants, yeast and even bacteria [1]. They mod-
ulate many cellular processes by limited cleavage of speciﬁc
protein substrates in response to calcium signaling. Some of
their roles include cytoskeletal remodeling during cell fusion
and cell motility, regulation of cell cycle progression, gene
expression, and apoptotic cell death. Calpains have been impli-
cated in many health problems including heart attack, stroke,
limb girdle muscular dystrophy, cancer and type II diabetes.
The two most extensively studied mammalian isoforms, l-
and m-calpain (calpains 1 and 2, respectively), are ubiquitously
and constitutively expressed. Both are heterodimers, each withAbbreviations: CAST1, calpastatin inhibitory domain 1; CAST2,
calpastatin inhibitory domain 2; CAST3, calpastatin inhibitory
domain 3; CAST4, calpastatin inhibitory domain 4; CAST1–4,
calpastatin polypeptide including domains 1–4
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doi:10.1016/j.febslet.2007.05.035an 80 k large subunit speciﬁc to the isoform, and a common
28 k subunit. Regulation of l- and m-calpain in vivo is poorly
understood. The process of calpain activation remains elusive,
as the overall intracellular calcium levels in vivo are not suﬃ-
cient to activate calpain in vitro [1–3]. There is speculation that
protein binding partners and/or post-translational modiﬁca-
tion are required to lower the calcium requirement for activa-
tion. There is also speculation that calpains are activated at
points in the cell by high local levels of calcium transported
across the plasma membrane or released from an intracellular
calcium store.
Calpastatin is the endogenous protein inhibitor of calpain
[4]. To date it is the only inhibitor that is completely speciﬁc
for calpain. It binds and inhibits calpain when calcium levels
are high, but is released when calcium levels fall. Calpastatin
contains ﬁve domains, four homologous domains (CAST1–4)
of about 140 amino acids in length that are capable of inhibit-
ing heterodimeric l- and m-calpain and a unique N-terminal
domain, termed domain L, with no inhibitory eﬀect [5–10].
Calpastatin is well conserved with greater than 70% identity
across mammalian species. It is encoded by a single gene that
has no obvious homologues.
Calpastatin is an unstructured protein that has a complex
interaction with calpain [5]. Each inhibitory domain contains
three well-conserved subdomains, A, B and C [4]. Subdomains
A and C interact at nM aﬃnity with the two penta-EF-hand
domains of calpain: A with domain IV on the large subunit
of calpain, and C with domain VI of the small subunit
[11,12]. Paradoxically, subdomain B, the subdomain responsi-
ble for inhibition, interacts weakly with calpain in the absence
of its ﬂanking A and C regions [7,13,14].
Previous work showed that all four inhibitory domains
(CAST1–4) bind tightly to calpain, however accurate quantiﬁ-
cation of their aﬃnity was not published [8,15]. In this study
we have used surface plasmon resonance to measure the kinetic
constants of individual CAST inhibitory domains and recom-
binant m-calpain. By using m-calpain with an active site muta-
tion we have eliminated the complications of autoproteolysis
and inhibitor digestion. In addition, the binding capacity of
calpastatin for calpain was determined.2. Materials and methods
2.1. Cloning of individual calpastatin inhibitory domains and calpastatin
minus domain L (CAST1–4) fused to a C-terminal Ecoil peptide
The Ecoil:Kcoil de novo coiled–coil interaction was used to immobi-
lize calpastatin on the surface of the Biacore CM5 chip so that the cal-
pastatin was ﬂexible and accessible to calpain (Fig. 1) [16]. Theblished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic outline of the Ecoil:Kcoil system used for kinetic
analysis following the method of Tripet et al. [27]. (A) Preparation of
the CM5 chip. Firstly the Kcoil peptide (red) is immobilized through
its N-terminal cysteine to the chip surface via a thio-ether bond.
Calpastatin inhibitory domain(s) (purple) followed by the Ecoil
peptide (green) and a C-terminal His-tag (brown) is then injected
and binds to the chip through the coiled–coil interaction. (B and C)
Calpain (blue) is injected and binds to the immobilized calpastatin in
the presence of calcium (yellow dots). (D) Calcium is removed by
injecting buﬀer containing EDTA, signiﬁed by a cross on the yellow
dot. Calpain dissociates from calpastatin in the absence of calcium and
the calpastatin-bound chip is regenerated.
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reaction (PCR) from a clone of rat calpastatin cDNA lacking domain
L (CAST1–4) supplied by Dr. Simon Arthur using the following prim-
ers: 5 0CAST1 ATTCCGCTCG AGAAGCTTCC TAGGCGAACT T-
TCCCCAGTA GACTT, 3 0CAST1 TTCAGATGAC CCCTTTTAAG
TGGATCCTTC GAAGAGCTCG CCTTA, 5 0CAST2 AGAAGCT-
TCC TAGGTATGTAGGT TGGACAAAAT CTGC, 3 0CAST2 CG-
TCTAAAAC AGGTTGGATG TATGGATCCT TCGAAGAGCT
CGCCTTA, 5 0CAST3 AGAAGCTTCC TAGGTGCAGG ACTGG-
AGAAG TCCTG, 3 0CAST3 GTCCTGAAGA GGTCAGGACG
TGGATCCTTC GAAGAGCTCG CCTTA, 5 0CAST4 ATTCCGC-
TCG AGAAGCTTCC TAGGGCTATC CAAGTCTTCT GAGAG,
3 0CAST4 GAGAGTCTTC TGAACCTATC GGGATCCTTC GAA-
GAGCTCG CCTTA. Inhibitory domains 1 and 4 (CAST1 and 4,
respectively) and CAST1–4 were each cloned into the NdeI and XhoI
sites of the pET24d expression vector (Novagen), and inhibitory do-
mains 2 and 3 (CAST2 and 3, respectively) were each cloned into the
NcoI and XhoI sites of the pET24a expression vector (Novagen). Both
expression vectors provided a C-terminal histidine tag. Using the AvrII
and XhoI sites of the clones, the DNA fragment coding for the Ecoil
peptide was PCR ampliﬁed and inserted between the inhibitory do-
main and the histidine tag [16].
2.2. Protein expression and puriﬁcation
Recombinant inactive m-calpain with an N-terminally truncated
small subunit (C105S 80 k/21 k) was expressed and puriﬁed as previ-
ously described [17]. Plasmids containing the CAST1 through
4 + Ecoil and CAST1–4 + Ecoil were transfected into Escherichia coli
BL21(DE3) (Novagen) by electroporation. LB media (25 ml) was inoc-
ulated from a single colony for growth overnight under kanamycin
selection before seeding 1 L of LB/kanamycin broth. The broth was
grown to an OD600 of 0.8–1.0 at 37 C. Protein expression was induced
by addition of 0.4 mM IPTG for 3 h. The cells were collected, resus-
pended in lysis buﬀer (25 mM Tris–HCl at pH 7.6, 5 mM EDTA,
5% glycerol, 10 mM b-mercaptoethanol, 100 lM phenylmethylsulfonyl
ﬂuoride) and lysed through sonication. The soluble fraction was heated
to 85 C for 15 min. Insoluble matter was removed by centrifugation,
and the soluble fraction applied to a 5 ml-Ni2+-chelating agarose resin
column (Qiagen). The column was washed with two column volumesof 25 mM Tris–HCl at pH 7.6, 2% glycerol, 500 mM NaCl buﬀer con-
taining 5 mM imidazole and eluted with the same buﬀer containing an
additional 250 mM imidazole. The CAST-containing fractions, identi-
ﬁed using A280 and SDS–PAGE analysis, were aliquoted and ﬂash fro-
zen. Each inhibitory domain was puriﬁed in a similar manner.
2.3. Expression and puriﬁcation of CAST1–4
CAST1–4 + Ecoil was produced in the same way as the individual
inhibitory domains, except that the heat-treated supernatant was ﬁl-
tered through a 0.45 lm ﬁlter and fractionated by Sephacryl S-300
(Pharmacia) size-exclusion chromatography on a 120 ml HiPrep 16/
60 column eluted with 25 mM sodium acetate (pH 4.5) containing
0.5 M NaCl. Fractions containing CAST1–4 were identiﬁed using
SDS–PAGE analysis. Some of the CAST1–4 aggregated and precipi-
tated under these conditions and was recovered by centrifugation at
16000 rpm in a Beckman JA25.5 rotor for 45 min. The pellet was
resuspended in denaturing buﬀer (8 M Urea, 25 mM Tris–HCl pH
7.6, 100 mM NaCl, 2% glycerol, 5 mM imidazole). The resuspended
CAST1–4 was applied to 5 ml of Ni2+-chelating resin, washed with
denaturing buﬀer followed by 10 column volumes of non-denaturing
buﬀer (lacking urea), and batch eluted with 250 mM imidazole (pH
7.6) in the same buﬀer.
2.4. Real-time binding analysis using biosensor technology
The Ca2+-dependent binding of inactive rat m-calpain (C105S 80
k/21 k) to the diﬀerent CAST constructs was performed using the BIA-
core 3000 Surface Plasmon Resonance Spectrometer (GE Healthcare).
Kcoil peptide was immobilized onto the surface of a CM5 biosensor
chip via a thio-ether bond from the N-terminal cysteine using malei-
mide coupling [18]. Calpastatin-Ecoil constructs were then injected
and bound to the surface of the chip via the Ecoil:Kcoil interaction
at a density of about 30 RU [16]. Injections were done at a ﬂow rate
of 20 ll/min at a concentration of approximately 10 ng/ml, in the BIA-
core running buﬀer HBS-EP (10 mM HEPES–HCl pH 7.4, 150 mM
NaCl, 3 mM EDTA, 0.0005% v/v surfactant P20 (BIAcore Life Sci-
ences)). To monitor the association and dissociation of calpain with
calpastatin, the running buﬀer was modiﬁed to include 1 mM DTT
and a 1 mM excess of CaCl2 over EDTA, which were at concentrations
of 4 mM and 3 mM, respectively. Calpain was diluted from a 3 mg/ml
stock in HBS-EP to concentrations 10-fold higher than were tested,
and then diluted 10-fold in calcium-containing buﬀer immediately
prior to injection. Injections were performed at a ﬂow rate of 40
ll/min with a 300 s association period and a minimum of 200 s for dis-
sociation. The chips were regenerated by injecting HBS-EP at a ﬂow
rate of 40 ll/min until a baseline was reached.3. Results
3.1. Puriﬁcation of calpastatin inhibitory domains
During its puriﬁcation, CAST1–4 precipitated in the frac-
tions from size-exclusion chromatography. This precipitate
was recovered by centrifugation and refolded on the Ni2+-aga-
rose column. Although much of the CAST1–4 remained in the
supernatant, this fraction was sacriﬁced because it was con-
taminated by calpastatin degradation products that were diﬃ-
cult to remove. The individual inhibitory domains were
substantially puriﬁed by the two-step heat-denaturation and
nickel aﬃnity chromatography procedure. Further chromatog-
raphy was unnecessary because the binding between the Ecoil-
tagged CAST and the Kcoil on the chip served as a ﬁnal highly
speciﬁc puriﬁcation step.3.2. Determination of the binding constants of the calpastatin
inhibitory domains for m-calpain
The main objective of this study was to measure the aﬃnity
of each of the four inhibitory domains for m-calpain using sur-
face plasmon resonance. This method allowed direct observa-
tion of the association (kon) and dissociation (koﬀ) of inactive
Table 1
Kinetic parameters for the interaction of calpain with individual
calpastatin inhibitory domains
Calpastatin domain kon (M
1s1) koﬀ (s
1) Kd (M)
1 2 · 107 9 · 105 4.5 · 1012
2 3 · 106 1 · 102 4 · 109
3 5 · 106 3 · 103 6 · 1010
4 6.5 · 106 3 · 104 5 · 1011
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onto the ﬂow cell surface (Fig. 1). For each of the four inhib-
itory domains, when calpain was injected the response units in-
creased with increasing enzyme concentration (Fig. 2).
Qualitatively, the relative tightness of the interaction of calpain
with each CAST domain is easily observable from the associ-
ation and dissociation phases of the titration curves. When cal-
pain is injected onto CAST1 the binding signal increases very
rapidly even at the lowest concentrations (200 and 400 pM)
until saturation is reached at concentrations as low as 2 and
4 nM. In contrast, when similar concentrations of calpain
(330 pM to 3.3 nM) are injected onto CAST2, CAST3, and
CAST4 all the binding curves display a much slower and grad-
ual growth which barely reaches saturation at the highest con-
centration tested. This suggests that CAST1 has the largest kon
value and that CAST2 and 3 and CAST 4 have smaller kon val-
ues. The kon values calculated using the BIAEVALUATION
3.1 software suite (Table 1) corroborate that CAST1 has the
largest kon value (2 · 107 M1/s1), while CAST2 has the
smallest kon value (3 · 106 M1/s1). The association rate con-
stants for CAST3 and CAST4 lie between those for CAST1
and CAST2 (5 · 106 and 6.5 · 106 M1/s1, respectively).
The diﬀerences between the dissociation curves of calpain
from each individual calpastatin domain are even more strik-
ing than those observed for the association phase of the inter-
action. When the injection of calpain was stopped at 300 s we
observed a decrease in response units of 60% for CAST2 andFig. 2. BIAcore analysis of the Ca2+-dependent interaction of inactive
m-calpain with bound CAST inhibitory domains. 30 RU of each
calpastatin inhibitory domain was immobilized on the ﬂow cell. For
each injection, calpain was diluted at least 10-fold immediately prior to
injection onto the chip in a Ca2+-containing buﬀer. Each injection
lasted 300 s at a ﬂow rate of 40 ll/min. Calpain was given a chance to
dissociate in the presence of calcium for a minimum of 200 s.
Regeneration of the chip after 500 s was performed by repeat injections
of buﬀer containing EDTA. The average response unit value is plotted
for each concentration and error bars indicating one standard
deviation are shown at 50 s intervals. (A) CAST1 + Ecoil. Calpain
was injected at concentrations of 200 pM (diamonds), 400 pM
(squares), 2 nM (triangles) and 4 nM (stars). Injections were done in
duplicate. (B) CAST2 + Ecoil. (C) CAST3 + Ecoil. (D) CAST4 + E-
coil. For these three panels calpain was injected at concentrations of
330 pM (diamonds), 820 pM (squares), 1.65 nM (triangles) and 3.3 nM
(stars). Injections were done in triplicate.30% for CAST3 at all calpain concentrations. In contrast, for
CAST1 and CAST4 when the injection was stopped the re-
sponse units remained constant for 200 s after the addition
of calpain was stopped, indicating that CAST1 and CAST 4
have much lower koﬀ values than CAST2 and 3. The large dif-
ferences in the Kd values of the inhibitory domains are mainly
a result of the very diﬀerent koﬀ values that range from
9 · 105 s1 for CAST1 to 1 · 102 s1 for CAST2. Despite
these diﬀerences, each inhibitory domain is considered a
tight-binding inhibitor with Kd values ranging from 4.5 pM
for CAST1 to 4 nM for CAST2.
3.3. Determination of the binding capacity of full-length
calpastatin for m-calpain
In addition to determining the kinetic parameters for the
binding of individual calpastatin inhibitory domains to cal-
pain, we sought to determine how many calpain molecules
CAST1–4 can bind. To study this, inactive m-calpain was in-
jected at high concentrations over ﬂow cells containing CAST1
or CAST1–4 (Fig. 3). Both binding curves have a sharp inﬂec-
tion point, with the response units increasing rapidly and line-
arly, and then leveling oﬀ after approximately 50 s. At 600 s
the injection was stopped. There was hardly any decrease in re-
sponse units observed for CAST1, but a noticeable decrease in
response units was seen for CAST1–4. The decrease in re-
sponse units for the full-length CAST indicates that both the
higher and lower-aﬃnity inhibitory domains are binding cal-
pain. The molar ratio of CAST1:CAST1–4 immobilized on
the chip surface was 0.83:1, therefore 0.83 moles of calpain
would be expected to bind to CAST1 for every 4 moles of cal-
pain that binds to CAST1–4. The ratio observed (0.79 moles of
calpain bound per mole of CAST1 for every 4 moles of calpainFig. 3. BIAcore analysis of the Ca2+-dependent interaction of inactive
rat m-calpain with CAST1 and CAST1–4. Each inhibitor was
immobilized in a separate ﬂow cell and the response units bound to
the chip were recorded. Inactive m-calpain (32.8 nM) in
Ca2+-containing buﬀer was injected at a ﬂow rate of 20 ll/min for
600 s. Calpain was given a chance to dissociate in the presence of
Ca2+-containing buﬀer for a minimum of 200 s. Regeneration was
performed by repeated injections of buﬀer containing EDTA. Injec-
tions were done in triplicate and the resulting error bars are smaller
than the symbols.
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CAST1–4, indicating that each inhibitory domain in full-
length calpastatin-bound a calpain.4. Discussion
In this study we quantiﬁed the kinetic parameters of each
calpastatin inhibitory domain’s interaction with m-calpain.
Previous investigations into the binding kinetics had deter-
mined that the CAST inhibitory domains are all tight-binding
inhibitors [8,15]. These studies measured calpain activity in the
presence of calpastatin by following the digestion of casein
[19]. This assay was not suﬃciently sensitive to quantify the
interaction beyond identifying calpastatin as an inhibitor with
sub-nanomolar aﬃnity for calpain. The relative binding
strengths of each inhibitory domain against m-calpain were
determined in this study, and the Kd values found here agree
with the accepted order of binding strengths (CAST1 >
4 > 3 > 2) [8,15]. An advantage of using the BIAcore system
to determine kinetic parameters is that both kon and koﬀ values
could be determined from the experimental data, and koﬀ was
not calculated from the Kd and kon as in other methods. Sur-
prisingly, the aﬃnities of the diﬀerent inhibitory domains vary
over three orders of magnitude as a result of large diﬀerences
in their koﬀ values, which range from 10
2 to 105 s1. It
should be noted that the koﬀ values for the tightest binding do-
mains, domains 1 and 4, are so small that they are at the limit
of what can be accurately modeled using the BIAcore.
Previous studies determined that endogenous calpastatin
inhibited calpain in a 4:1 ratio of calpain:calpastatin. However,
the inhibitory capacity of the calpastatin protein as a whole
was not clear because it is cleaved in vitro by calpain or cas-
pase to yield the individual CAST domains that retain inhibi-
tory activity [20–23]. By using an inactive mutant of calpain
and the BIAcore system we were able to test the binding of cal-
pain to calpastatin (CAST1–4) without the complications of
calpastatin digestion. Because the molecular weight of the
calpastatin construct is known, and the response unit value
is directly proportional to the protein mass at the surface of
the chip, it was possible to estimate the maximum response
units if all four inhibitory domains of CAST1–4 bind calpain.
When the chip was saturated with calpain the response units
observed corresponded closely with what was to be expected
if all four inhibitory domains bound calpain. This indicates
that calpastatin is capable of binding and inhibiting four mol-
ecules of calpain without any modiﬁcations through proteoly-
sis.
The presence of multiple isoforms of calpastatin expressed in
mammals suggests that the diﬀerent domains in calpastatin
with seemingly identical function serve diﬀerent purposes.
Four diﬀerent promoters and alternative splicing allow for
the expression of tissue-speciﬁc isoforms such as erythrocyte
calpastatin lacking domain L and inhibitory domain 1, and a
testis-speciﬁc isoform that lacks domain L, domain 1 and a
portion of domain 2, as well as the ubiquitous isoform contain-
ing all ﬁve domains [24–26]. The speciﬁc roles of the diﬀerent
isoforms remain unclear, and no functional diﬀerences
between the inhibitory domains have been discovered. One
possibility is the individual CAST domains have diﬀerent aﬃn-
ities for heterodimeric ‘‘tissue-speciﬁc’’ calpains. Once these
isoforms of calpain are isolated or produced recombinantlythe BIAcore system described here provides an excellent sys-
tem for characterizing the interactions. This system also pro-
vides us with a tool to evaluate the eﬀect of point-mutations
and domain alterations on the kinetic constants with calpain,
which may have signiﬁcant value for structure–function analy-
sis.
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